Skip to main content

9 Result(s)

within Joseph P. Balthasar Remove this filter Biotechnology Remove this filter Pharmacy Remove this filter

and

  1. No Access

    Article

    Amgen v. Sanofi: Critical Impact on the Value of Innovative Science in Antibody Discovery

    Joseph P. Balthasar in The AAPS Journal (2023)

  2. No Access

    Article

    Targeted Delivery of Endosomal Escape Peptides to Enhance Immunotoxin Potency and Anti-cancer Efficacy

    This work describes use of anti-carcinoembryonic antigen antibodies (10H6, T84.66) for targeted delivery of an endosomal escape peptide (H6CM18) and gelonin, a type I ribosome inactivating protein. The viabili...

    Joseph Ryan Polli, ** Chen, Brandon M. Bordeau, Joseph P. Balthasar in The AAPS Journal (2022)

  3. No Access

    Article

    Investigation of the Influence of Protein-Losing Enteropathy on Monoclonal Antibody Pharmacokinetics in Mice

    Protein losing enteropathy (PLE), which is characterized by substantial loss of plasma proteins into the gastrointestinal (GI) tract, is a complication of a variety of GI diseases, including inflammatory bowel...

    Yujie Yang, Tommy R. Li, Joseph P. Balthasar in The AAPS Journal (2017)

  4. No Access

    Article

    Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer

    In this investigation, we test the hypothesis that treatment with sorafenib, an anti-angiogenic agent, decreases tumor vascularization and, consequently, hinders the delivery of monoclonal antibodies (mAb) to ...

    Veena A. Thomas, Joseph P. Balthasar in The AAPS Journal (2016)

  5. No Access

    Article

    Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro

    The time course of chemotherapeutic effect is often delayed relative to the time course of chemotherapeutic exposure. In many cases, this delay is difficult to characterize mathematically through the use of st...

    Evelyn D. Lobo, Joseph P. Balthasar in AAPS PharmSci (2015)

  6. No Access

    Article

    Evaluation of a Catenary PBPK Model for Predicting the In Vivo Disposition of mAbs Engineered for High-Affinity Binding to FcRn

    Efforts have been made to extend the biological half-life of monoclonal antibody drugs (mAbs) by increasing the affinity of mAb–neonatal Fc receptor (FcRn) binding; however, mixed results have been reported. O...

    Yang Chen, Joseph P. Balthasar in The AAPS Journal (2012)

  7. No Access

    Article

    Pharmacokinetic mAb–mAb Interaction: Anti-VEGF mAb Decreases the Distribution of Anti-CEA mAb into Colorectal Tumor Xenografts

    To date, there has been little investigation of the risk for drug–drug interactions involving monoclonal antibodies. The present work examined the effects of an anti-vascular endothelial growth factor (anti-VE...

    Lubna Abuqayyas, Joseph P. Balthasar in The AAPS Journal (2012)

  8. No Access

    Article

    Investigation of the Influence of FcRn on the Distribution of IgG to the Brain

    It has been suggested that the neonatal Fc receptor (FcRn) is a primary determinant of the distribution of IgG to the brain. In the present report, 125I-labeled 7E3, a monoclonal IgG1 antibody, was injected intra...

    Amit Garg, Joseph P. Balthasar in The AAPS Journal (2009)

  9. No Access

    Article

    Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia

    Intravenous administration of pooled, polyvalent human immunoglobulin (IVIG) has been used for over 20 years as a therapy for immune thrombocytopenia (ITP). IVIG is available in limited quantities, and clinica...

    Feng **, Zia R. Tayab, Joseph P. Balthasar in The AAPS Journal (2005)